Alkylating agent

DRUG CLASS:

Alkylating agent

News alerts, weekly reports and conference planners

Related drugs:

BRCA wild-type	Triple Negative Breast Cancer	BRCA wild-type	Triple Negative Breast Cancer	carboplatin + paclitaxel + cyclophosphamide Sensitive: C3 – Early Trials SG-BCC 2023 - 2 weeks (New C3) carboplatin + paclitaxel + cyclophosphamide Sensitive : C3 SG-BCC 2023 - 2wk	carboplatin + paclitaxel + cyclophosphamide Sensitive: C3 – Early Trials SG-BCC 2023 - 2 weeks carboplatin + paclitaxel + cyclophosphamide Sensitive : C3 SG-BCC 2023 - 2 weeks - (New C3)
SLFN11 overexpression	Small Cell Lung Cancer	SLFN11 overexpression	Small Cell Lung Cancer	lurbinectedin Sensitive: D – Preclinical AACR 2023 - 2 weeks (New D) lurbinectedin Sensitive : D AACR 2023 - 2wk	lurbinectedin Sensitive: D – Preclinical AACR 2023 - 2 weeks lurbinectedin Sensitive : D AACR 2023 - 2 weeks - (New D)
POU2F3 overexpression	Small Cell Lung Cancer	POU2F3 overexpression	Small Cell Lung Cancer	lurbinectedin Sensitive: D – Preclinical AACR 2023 - 2 weeks (New D) lurbinectedin Sensitive : D AACR 2023 - 2wk	lurbinectedin Sensitive: D – Preclinical AACR 2023 - 2 weeks lurbinectedin Sensitive : D AACR 2023 - 2 weeks - (New D)
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	cyclophosphamide + albumin-bound paclitaxel + epirubicin Sensitive: C3 – Early Trials Nanomedicine - 3 weeks (New C3) cyclophosphamide + albumin-bound paclitaxel + epirubicin Sensitive : C3 Nanomedicine - 3wk	cyclophosphamide + albumin-bound paclitaxel + epirubicin Sensitive: C3 – Early Trials Nanomedicine - 3 weeks cyclophosphamide + albumin-bound paclitaxel + epirubicin Sensitive : C3 Nanomedicine - 3 weeks - (New C3)
No biomarker	Breast Cancer	No biomarker	Breast Cancer	docetaxel + doxorubicin hydrochloride + cyclophosphamide Sensitive: A1 - Approval docetaxel + doxorubicin hydrochloride + cyclophosphamide Sensitive : A1	docetaxel + doxorubicin hydrochloride + cyclophosphamide Sensitive: A1 - Approval docetaxel + doxorubicin hydrochloride + cyclophosphamide Sensitive : A1
No biomarker	Burkitt Lymphoma	No biomarker	Burkitt Lymphoma	cyclophosphamide Sensitive: A1 - Approval cyclophosphamide Sensitive : A1	cyclophosphamide Sensitive: A1 - Approval cyclophosphamide Sensitive : A1
No biomarker	Retinoblastoma	No biomarker	Retinoblastoma	cyclophosphamide Sensitive: A1 - Approval cyclophosphamide Sensitive : A1	cyclophosphamide Sensitive: A1 - Approval cyclophosphamide Sensitive : A1
No biomarker	Neuroblastoma	No biomarker	Neuroblastoma	melphalan Sensitive: A1 - Approval melphalan Sensitive : A1	melphalan Sensitive: A1 - Approval melphalan Sensitive : A1
No biomarker	Neuroblastoma	No biomarker	Neuroblastoma	cyclophosphamide Sensitive: A1 - Approval cyclophosphamide Sensitive : A1	cyclophosphamide Sensitive: A1 - Approval cyclophosphamide Sensitive : A1
No biomarker	Brain Cancer	No biomarker	Brain Cancer	lomustine Sensitive: A1 - Approval lomustine Sensitive : A1	lomustine Sensitive: A1 - Approval lomustine Sensitive : A1
No biomarker	Astrocytoma	No biomarker	Astrocytoma	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1
No biomarker	Ependymoma	No biomarker	Ependymoma	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1
No biomarker	Medulloblastoma	No biomarker	Medulloblastoma	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1
No biomarker	Non-Hodgkin’s Lymphoma	No biomarker	Non-Hodgkin’s Lymphoma	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	prednisone + thalidomide + melphalan Sensitive: A1 - Approval prednisone + thalidomide + melphalan Sensitive : A1	prednisone + thalidomide + melphalan Sensitive: A1 - Approval prednisone + thalidomide + melphalan Sensitive : A1
No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	trabectedin Sensitive: A1 - Approval trabectedin Sensitive : A1	trabectedin Sensitive: A1 - Approval trabectedin Sensitive : A1
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	lurbinectedin Sensitive: A1 - Approval lurbinectedin Sensitive : A1	lurbinectedin Sensitive: A1 - Approval lurbinectedin Sensitive : A1
No biomarker	Chronic Myeloid Leukemia	No biomarker	Chronic Myeloid Leukemia	busulfan Sensitive: A1 - Approval busulfan Sensitive : A1	busulfan Sensitive: A1 - Approval busulfan Sensitive : A1
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	trabectedin Sensitive: A1 - Approval trabectedin Sensitive : A1	trabectedin Sensitive: A1 - Approval trabectedin Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	melphalan flufenamide Sensitive: A1 - Approval melphalan flufenamide Sensitive : A1	melphalan flufenamide Sensitive: A1 - Approval melphalan flufenamide Sensitive : A1
No biomarker	Leiomyosarcoma	No biomarker	Leiomyosarcoma	trabectedin Sensitive: A1 - Approval trabectedin Sensitive : A1	trabectedin Sensitive: A1 - Approval trabectedin Sensitive : A1
No biomarker	Liposarcoma	No biomarker	Liposarcoma	trabectedin Sensitive: A1 - Approval trabectedin Sensitive : A1	trabectedin Sensitive: A1 - Approval trabectedin Sensitive : A1
No biomarker	Glioma	No biomarker	Glioma	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1
No biomarker	Glioblastoma	No biomarker	Glioblastoma	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	bendamustine RTD Sensitive: A1 - Approval bendamustine RTD Sensitive : A1	bendamustine RTD Sensitive: A1 - Approval bendamustine RTD Sensitive : A1
No biomarker	Non-Hodgkin’s Lymphoma	No biomarker	Non-Hodgkin’s Lymphoma	bendamustine RTD Sensitive: A1 - Approval bendamustine RTD Sensitive : A1	bendamustine RTD Sensitive: A1 - Approval bendamustine RTD Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1
No biomarker	Peritoneal Cancer	No biomarker	Peritoneal Cancer	melphalan Sensitive: A2 - Guideline melphalan Sensitive : A2	melphalan Sensitive: A2 - Guideline melphalan Sensitive : A2
No biomarker	Peritoneal Cancer	No biomarker	Peritoneal Cancer	cyclophosphamide Sensitive: A2 - Guideline cyclophosphamide Sensitive : A2	cyclophosphamide Sensitive: A2 - Guideline cyclophosphamide Sensitive : A2
No biomarker	Fallopian Tube Cancer	No biomarker	Fallopian Tube Cancer	melphalan Sensitive: A2 - Guideline melphalan Sensitive : A2	melphalan Sensitive: A2 - Guideline melphalan Sensitive : A2
No biomarker	Fallopian Tube Cancer	No biomarker	Fallopian Tube Cancer	cyclophosphamide Sensitive: A2 - Guideline cyclophosphamide Sensitive : A2	cyclophosphamide Sensitive: A2 - Guideline cyclophosphamide Sensitive : A2
No biomarker	Medulloblastoma	No biomarker	Medulloblastoma	cisplatin + cyclophosphamide + vincristine Sensitive: A2 - Guideline cisplatin + cyclophosphamide + vincristine Sensitive : A2	cisplatin + cyclophosphamide + vincristine Sensitive: A2 - Guideline cisplatin + cyclophosphamide + vincristine Sensitive : A2
No biomarker	Medulloblastoma	No biomarker	Medulloblastoma	cisplatin + vincristine + lomustine Sensitive: A2 - Guideline cisplatin + vincristine + lomustine Sensitive : A2	cisplatin + vincristine + lomustine Sensitive: A2 - Guideline cisplatin + vincristine + lomustine Sensitive : A2
No biomarker	Sarcoma	No biomarker	Sarcoma	trabectedin Sensitive: A2 - Guideline trabectedin Sensitive : A2	trabectedin Sensitive: A2 - Guideline trabectedin Sensitive : A2
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	cyclophosphamide Sensitive: A2 - Guideline cyclophosphamide Sensitive : A2	cyclophosphamide Sensitive: A2 - Guideline cyclophosphamide Sensitive : A2

Alkylating agent

Alkylating agent

Associations(187)

Associations
(187)